Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: Comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells

APMIS

Volumn 115, Issue 11, 2007, Pages 1194-1205

  Kuncová, Jitka ^a   Urban, Michael ^a   Mandys, Václav ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CD44; Grade of tumour; Ki 67; p53; Urothelial cancer

Indexed keywords

HERMES ANTIGEN; PROTEIN P53;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CELL FUNCTION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR CELL; TUMOR DIFFERENTIATION;

ANTIGENS, CD; ANTIGENS, CD44; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; GLYCOPROTEINS; HUMANS; KI-67 ANTIGEN; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 37349114461     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0643.2007.00602.x     Document Type: Article

References (47)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005 55 : 10 30.
2. Williams SG, Stein JP. Molecular pathways in bladder cancer. Urol Res 2004 32 : 373 85.
3. Pashos CL, Botteman MF, Laskin BJ, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002 10 : 311 22.
4. Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control 2000 7 : 335 9.
5. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001 19 : 666 75.
6. Otto T, Goepel M, Heider KH, Rübben H. Prognostic factors for bladder cancer. Urol Res 1995 23 : 137 41.
7. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, et al. Normal human tissues, in addition to some tumours, express multiple different CD44 isoforms. Cancer Res 1994 54 : 4539 46.
8. Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994 124 : 71 82.
9. Goodison S, Tarin D. Current status of CD44 variant isoforms as cancer diagnostic markers. Histopathology 1998 32 : 1 6.
10. Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 1998 51 : 191 200.
11. Borland G, Ross JA, Guy K. Forms and functions of CD44. Immunology 1998 93 : 139 48.
12. Goodfellow PN, Banting G, Wiles MV, Tunnacliffe A, Parkar M, Solomon E, et al. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol 1982 12 : 659 63.
13. Southgate J, Trejdosiewicz LK, Smith B, Selby PJ. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer 1995 62 : 449 56.
14. Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett 1995 89 : 81 7.
15. Müller M, Heicappell R, Habermann F, Kaufmann M, Steiner U, Miller K. Expression of CD44v2 in transitional cell carcinoma of the urinary bladder and in urine. Urol Res 1997 25 : 187 92.
16. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004 91 : 196 205.
17. Li Y, Liu W, Hayward SW, Cunha GR, Baskin LS. Plasticity of the urothelial phenotype: effects of gastro-intestinal mesenchyme/stroma and implications for urinary tract reconstruction. Differentiation 2000 66 : 126 35.
18. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998 186 : 157 64.
19. Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ. Expressions of E-cadherin and exon v-6 containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 1995 153 : 2025 8.
20. Ross JS, Delrosario AD, Bui HX, Kallakury BVS, Okby NT, Figge J. Expression of CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol 1996 9 : 854 60.
21. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996 149 : 873 82.
22. Ioachim E, Charchanti A, Stavropoulos N, Athanassiou E, Bafa M, Agnantis NJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. Anticancer Res 2002 22 : 3383 8.
23. Toma V, Hauri D, Schmid U, Ackermann D, Maurer R, Alund G, et al. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 1999 155 : 1427 32.
24. Sobin LH, Wittekind Ch. TNM classification of malignant tumours 6th edition). New York : Wiley-Liss, Inc., 2002.
25. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997 80 : 1472 81.
26. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A, et al. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade1 papillary carcinomas of the bladder. Cancer 2002 95 : 784 90.
27. Hutton KAR, Trejdosiewicz LK, Thomas DFM, Southgate J. Urothelial tissue culture for bladder reconstruction: an experimental study. J Urol 1993 150 : 721 5.
28. Southgate J, Hutton KAR, Thomas DFM, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994 71 : 583 93.
29. Limas C. Proliferative state of the urothelium with benign and atypical changes. Correlation with transferrin and epidermal factor receptors and blood group antigens. J Pathol 1993 171 : 39 47.
30. Marceau N. Cell lineages and differentiation programs in epidermal, urothelial and hepatic tissues and their neoplasms. Lab Invest 1990 63 : 4 20.
31. Varley C, Hill G, Pellegrin S, Shaw NJ, Selby PJ, Trejdosiewicz LK, et al. Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp Cell Res 2005 306 : 216 29.
32. Esrig D, Spruck CH 3rd., Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumour grade, and stage in bladder cancer. Am J Pathol 1993 143 : 1389 97.
33. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994 70 : 496 500.
34. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, et al. Prognostic value of p53 overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995 13 : 1384 90.
35. Matsumura Y, Sugiyama M, Matsumura S, Hayle AJ, Robinson P, Smith JC, et al. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 1995 177 : 11 20.
36. Alam TN, O'Hare MJ, Laczko I, Freeman A, Al-Beidh F, Masters JR, et al. Differential expression of CD44 during human prostate epithelial cell differentiation. J Histochem Cytochem 2004 52 : 1083 90.
37. Kuncová J, Kostrouch Z, Viale M, Revoltella R, Mandys V. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Folia Biol 2005 51 : 3 11.
38. Gotoda T, Matsumura Y, Kondo H, Ono H, Kanamoto A, Kato H, et al. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut 2000 46 : 14 19.
39. Nguyen VN, Mirejovský T, Melínová L, Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relations to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 2000 47 : 400 8.
40. Ylagan LR, Scholes J, Demopoulos R. CD44. A marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 2000 124 : 212 5.
41. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991 138 : 867 73.
42. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984 133 : 1710 5.
43. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 2000 88 : 2598 605.
44. Cattoretti G, Becker MGH, Key G, Duchrow M, Schlueter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1991 168 : 357 63.
45. Lipponen PK, Eskelinen MJ, Nordline S. Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S phase fraction and DNA ploidy. Eur J Cancer 1991 27 : 877 81.
46. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991 351 : 453 6.
47. Ørntoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998 26 : 223 33.